Suchergebnisse - "Fleischmann, Roy"

PubPharm (423)

1

TYK2 : an emerging therapeutic target in rheumatic disease

enthalten in: Nature reviews. Rheumatology | 2024

von Morand, E. | Merola, J. | Tanaka, Y. | +2

2

Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis : 5-Year Data from SELECT-COMPARE

enthalten in: Rheumatology and therapy | 2024

von Fleischmann, R. | Blanco, R. | Van den Bosch, F. | +7

3

Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk-Enriched Rheumatoid Arthritis Patients

enthalten in: Arthritis & rheumatology (Hoboken, N.J.) | 2024

von Charles-Schoeman, C. | Fleischmann, R. | Mysler, E. | +13

4

Publisher Correction : Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician

enthalten in: Nature reviews. Rheumatology | 2024

von Szekanecz, Z. | Buch, M. | Charles-Schoeman, C. | +6

ErratumFor: Nat Rev Rheumatol. 2024 Feb;20(2):101-115. - PMID 38216757

5

Efficacy and safety of JAK inhibitors in rheumatoid arthritis : update for the practising clinician

enthalten in: Nature reviews. Rheumatology | 2024

von Szekanecz, Z. | Buch, M. | Charles-Schoeman, C. | +6

ErratumIn: Nat Rev Rheumatol. 2024 Feb 1;:. - PMID 38302658

6

Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs : two phase 3 randomised trials (contRAst 1 and contRAst 2)

enthalten in: Annals of the rheumatic diseases | 2023

von Fleischmann, R. | van der Heijde, D. | Strand, V. | +19

7

Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies : a phase III randomised trial (contRAst 3)

enthalten in: Annals of the rheumatic diseases | 2023

von Taylor, P. | Weinblatt, M. | McInnes, I. | +18

8

Is There a Role for Vagal Nerve Stimulation in the Treatment of Rheumatoid Arthritis?

enthalten in: Arthritis & rheumatology (Hoboken, N.J.) | 2023

von Fleischmann, R.

CommentOn: Arthritis Rheumatol. 2023 Dec;75(12):2107-2115. - PMID 37390360

9

Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis

enthalten in: Rheumatology (Oxford, England) | 2023

von Burmester, G. | Strand, V. | Kivitz, A. | +5

10

Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis : a phase 3, open-label, randomised, parallel-group study

enthalten in: The Lancet. Rheumatology | 2023

von Fleischmann, R. | Saikali, W. | Lakhanpal, S. | +6

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[43]